App-Quantinova.ai

EGPA with Unique Manifestations

M. Williams - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Otolaryngology

Heart muscle disease

Mepolizumab

IV Epinephrine Induced Coronary Vasospasm

I. Kirti - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Heart muscle disease

Diphenhydramine

Pulmonary Histoplasmosis: A Pulmonary Malignancy Mimic

H. Zia - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

Diacylglycerol lipase / beta

Association of left atrial ejection fraction and cardiovascular outcomes in Asian patients with hypertrophic cardiomyopathy

N Y Sari - European Society of Cardiology (ESC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Effects of SGLT2 inhibitors on heart failure symptoms, quality of life and exercise capacity in patients with heart failure and preserved ejection fraction: A meta-analysis

L R C Merin - European Society of Cardiology (ESC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Diagnosing Localized Right Ventricular Pericardial Tamponade After Ventricular Assist Device Placement

Van Phan - American Society of Anesthesiologists (ASA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

Epinephrine

Small Leucine-rich Proteoglycan Asporin Represses Cardiac And Pulmonary Fibroblast Activation

Lejla Medzikovic - American Society of Anesthesiologists (ASA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Heart muscle disease

Angiotensin II

The Role Of Cd38 As A Therapeutic Target For Protection Against Doxorubicin-induced Cardiotoxicity Through Nad Boosting

Thais Peclat - American Society of Anesthesiologists (ASA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Nicotinamide

Adrenergic Activation Differs Across The Lifecourse In Response To Isoproterenol In Mice

Jacob Zumo - American Society of Anesthesiologists (ASA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Isoproterenol

Metal-Ion Transporter SLC39A14 Is Required for Cardiac Iron Loading in the Hjv Mouse Model of Iron Overload

Qingli Liu - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Heart muscle disease

Nicardipine Hydrochloride

Post-Transfusion Takotsubo Cardiomyopathy

Krishna G Badami - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Heart muscle disease

Catecholamine

Elevated Levels of Low Density Lipoprotein (LDL) Trigger VWF Self-Association into Fibers and Bundles and Potentiate Microvascular Thrombosis

Dominic W. Chung - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Heart muscle disease

Hemostatic Solution

Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

Paul Saultier - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Heart muscle disease

N/A

Colchicine Protects Against Cardiomyopathy in Humanized Mouse Model for Sickle Cell Disease

Enrica Federti - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Heart muscle disease

Colchicine

No Cardiomyopathy or Skeletal Muscle Weakness in an Organismal Model of Barth Syndrome - Is Metabolism the Basis for Its Neutropenia?

Usua Oyarbide Cuervas-Mons - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Heart muscle disease

TP53

Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML)

Maximilian F. Stahl - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

daunorubicin + cytarabine

Differences in Light Chain (AL) Amyloidosis Epidemiology By Race and Ethnicity

Ashima Singh - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Heart muscle disease

N/A

Acute Care Utilization Among Individuals with Sickle Cell Disease and Related Cardiopulmonary and Renal Complications

Ashima Singh - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Heart muscle disease

N/A

Duvelisib for Critically-Ill Patients with COVID-19 Disease: An Investigator-Initiated, Randomized, Placebo-Controlled Double-Blind Pilot Trial

Scott R. Goldsmith - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Duvelisib

Characterization and Outcomes of Small for Gestational Age Very Low Birth Weight Infants

Kate E. Ramm - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

N/A

Filters

3340 Abstracts